Klaria Pharma: The company's present value is approx. SEK 812 million in external valuation, corresponding to approx. SEK 1.88 per share after completion of the rights issue

Honeybadger published a valuation report prepared on behalf of and for remuneration from Klaria, estimating the ordinary shares at approximately SEK 812 million, or SEK 1.88 per share, in its base scenario. The estimate follows a modeled rights issue of approximately SEK 111.1 million, corresponding to subscription and guarantee commitments; TO1 warrants were valued separately. The available article text ends while describing the valuation basis.

Analysis

The key market implication is not the headline valuation but whether the modeled royalty stream is independently supportable and whether the financing assumed in the model actually closes on its stated terms. Because Klaria commissioned and paid for the report, treat the estimate as an advocacy-sensitive input—not fresh evidence of realizable value. A royalty-based model is especially exposed to partner execution, launch timing, sales penetration, royalty terms, and discount-rate assumptions; small changes can materially alter present value without changing near-term cash receipts.

Near term, the report may anchor investor expectations around the financing, but it does not itself create cash or validate the underlying commercial assumptions. Over the next 1–3 months, subscription/guarantee completion and any disclosure of the model’s royalty inputs matter more than the headline estimate. Over 6–18 months, partner milestones and evidence of commercialization would be the substantive validation points. A less favorable financing outcome, delayed milestones, or weaker-than-modeled royalty economics would reverse the narrative; the supplied article excerpt does not include enough detail to assess those probabilities.

Key Decisions for Investors

• Do not chase KLAR on the valuation publication alone. First obtain the full report and test royalty rates, addressable sales, launch timing, probability adjustments, discount rate, and treatment of the modeled rights issue and TO1 warrants.
• Treat financing completion as the immediate catalyst to monitor: verify subscription proceeds, guarantee performance, final dilution, and any residual funding need before assigning value to the modeled per-share figure.
• Keep KLAR on a catalyst watch rather than initiating a directional position on this evidence. Reassess only if independently verifiable partner or commercialization milestones support the royalty assumptions; the thesis is falsified by material delays, reduced economics, or financing terms that increase dilution beyond the model.
• Contrarian check: the report may be over-weighted as a price anchor even though it is commissioned and contingent on future royalties. Conversely, if the full assumptions are conservative and later corroborated by operating milestones, the market may be underpricing the option value—but the excerpt does not establish that case.